» Articles » PMID: 14506392

Silymarin Retards the Progression of Alcohol-induced Hepatic Fibrosis in Baboons

Overview
Specialty Gastroenterology
Date 2003 Sep 25
PMID 14506392
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: GOAL/BACKGROUND: Hepatoprotective effects of silymarin in patients with alcoholic liver disease are controversial. For strict control, this was assessed in non-human primates. STUDY Twelve baboons were fed alcohol with or without silymarin for 3 years with a nutritionally adequate diet.

Results: Silymarin opposed the alcohol-induced oxidative stress (assessed by plasma 4-hydroxynonenal) and the rise in liver lipids and circulating ALT. Alcohol also increased hepatic collagen type I by 50% over the 3 years with a significant rise in mRNA for alpha1 (I) procollagen, both prevented by silymarin. There were corresponding morphologic changes: at 36 months, 2 of 6 animals fed alcohol had cirrhosis and 2 septal fibrosis, with perivenular fibrosis in 2, whereas with alcohol + silymarin, there was only 1 cirrhosis and 1 septal fibrosis, with perivenular fibrosis in 2, and virtually no lesions in the remaining 2.

Conclusions: Silymarin retards the development of alcohol-induced hepatic fibrosis in baboons, consistent with several positive clinical trials. The negative outcome observed in other trials possibly reflects poor compliance resulting in irregular or low silymarin intake. Thus, in view of the innocuity of silymarin, it might be advisable in future clinical studies to insure the controlled administration of sufficient amounts of silymarin.

Citing Articles

Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress-A Pilot Study.

Bosco G, Vezzoli A, Brizzolari A, Paganini M, Giacon T, Savini F Nutrients. 2024; 16(17).

PMID: 39275279 PMC: 11397684. DOI: 10.3390/nu16172965.


Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy.

Zhang C, Liu S, Yang M World J Hepatol. 2023; 15(2):180-200.

PMID: 36926234 PMC: 10011909. DOI: 10.4254/wjh.v15.i2.180.


Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.

Yang B, Yang X, Tan X, Lu L, Fan W, Barbier-Torres L Can J Gastroenterol Hepatol. 2022; 2022:6799414.

PMID: 36397950 PMC: 9666027. DOI: 10.1155/2022/6799414.


Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.

Lee H, Chang Y, Sung P, Yoon E, Lee H, Yoo J Clin Mol Hepatol. 2022; 28(3):425-472.

PMID: 35850495 PMC: 9293616. DOI: 10.3350/cmh.2022.0186.


Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Koltai T, Fliegel L J Evid Based Integr Med. 2022; 27:2515690X211068826.

PMID: 35018864 PMC: 8814827. DOI: 10.1177/2515690X211068826.